Vascular dysfunction in chronic obstructive pulmonary disease: current evidence and perspectives

References

• Curkendall SM, DeLuise C, Jones JK et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann. Epidemiol.16(1), 63–70 (2006).
   PubMed Web of Science ®Google Scholar
• McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax62(5), 411–415 (2007).
   PubMed Web of Science ®Google Scholar
• Mannino DM, Doherty DE, Sonia Buist A. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir. Med.100(1), 115–122 (2006).
   PubMed Web of Science ®Google Scholar
• Berger JS, Sanborn TA, Sherman W, Brown DL. Effect of chronic obstructive pulmonary disease on survival of patients with coronary heart disease having percutaneous coronary intervention. Am. J. Cardiol.94(5), 649–651 (2004).
   PubMed Web of Science ®Google Scholar
• Zvezdin B, Milutinov S, Kojicic M et al. A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest136(2), 376–380 (2009).
   PubMed Web of Science ®Google Scholar
• Sin DD, Man SFP. Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease. Can. J. Physiol. Pharmacol.83(1), 8–13 (2005).
   PubMed Web of Science ®Google Scholar
• Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ313, 711–715 (1996).
   PubMed Web of Science ®Google Scholar
• Lind L, Berglund L, Larsson A, Sundstrom J. Endothelial function in resistance and conduit arteries and 5-year risk of cardiovascular disease. Circulation123(14), 1545–1551 (2011).
   PubMed Web of Science ®Google Scholar
• Rubinshtein R, Kuvin JT, Soffler M et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur. Heart J.31(9), 1142–1148 (2010).
   PubMed Web of Science ®Google Scholar
• Blacher J, Guerin AP, Pannier B et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation99(18), 2434–2439 (1999).
   PubMed Web of Science ®Google Scholar
• Laurent S, Boutouyrie P, Asmar R et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension37(5), 1236–1241 (2001).
   PubMed Web of Science ®Google Scholar
• Mattace-Raso FU, van der Cammen TJ, Hofman A et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation113(5), 657–663 (2006).
   PubMed Web of Science ®Google Scholar
• Eickhoff P, Valipour A, Kiss D et al. Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.178(12), 1211–1218 (2008).
   PubMed Web of Science ®Google Scholar
• Barr RG, Mesia-Vela S, Austin JHM et al. Impaired flow-mediated dilation is associated with low pulmonary function and emphysema in ex-smokers – the emphysema and cancer action project (EMCAP) study. Am. J. Respir. Crit. Care Med.176(12), 1200–1207 (2007).
   PubMed Web of Science ®Google Scholar
• Clarenbach CF, Stöwhas AC, Mettler G et al. Is the severity of airflow limitation associated with vascular function in COPD? Respiration82, 69 (2011) (Abstract).
   Google Scholar
• Marchetti N, Ciccolella DE, Jacobs MR et al. Hospitalized acute exacerbation of COPD impairs flow and nitroglycerin-mediated peripheral vascular dilation. COPD8(2), 60–65 (2011).
   PubMedGoogle Scholar
• Sabit R, Bolton CE, Edwards PH et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.175(12), 1259–1265 (2007).
   PubMed Web of Science ®Google Scholar
• Maclay JD, Mcallister DA, Mills NL et al. Vascular dysfunction in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.180(6), 513–520 (2009).
   PubMed Web of Science ®Google Scholar
• McAllister DA, Maclay JD, Mills NL et al. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.176(12), 1208–1214 (2007).
   PubMed Web of Science ®Google Scholar
• Chang CL, Robinson SC, Mills GD et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax66(9), 764–768 (2011).
   PubMed Web of Science ®Google Scholar
• Høiseth AD, Neukamm A, Karlsson BD, Omland T, Brekke PH, Søyseth V. Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease. Thorax66(9), 775–781 (2011).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med.342(12), 836–843 (2000).
   PubMed Web of Science ®Google Scholar
• Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation109(11), 1349–1353 (2004).
   PubMed Web of Science ®Google Scholar
• Pai JK, Pischon T, Ma J et al. Inflammatory markers and the risk of coronary heart disease in men and women. N. Engl. J. Med.351(25), 2599–2610 (2004).
   PubMed Web of Science ®Google Scholar
• Wouters EF, Reynaert NL, Dentener MA, Vernooy JH. Systemic and local inflammation in asthma and chronic obstructive pulmonary disease: is there a connection? Proc. Am. Thorac. Soc.6(8), 638–647 (2009).
   PubMedGoogle Scholar
• Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.175(3), 250–255 (2007).
   PubMed Web of Science ®Google Scholar
• Broekhuizen R, Wouters EFM, Creutzberg EC, Schols AMWJ. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax61(1), 17–22 (2006).
   PubMed Web of Science ®Google Scholar
• Man SFP, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax61(10), 849–853 (2006).
   PubMed Web of Science ®Google Scholar
• De Torres JP, Pinto-Plata V, Casanova C et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest133(6), 1336–1343 (2008).
   PubMed Web of Science ®Google Scholar
• Walter RE, Wilk JB, Larson M et al. Systemic inflammation and COPD: the Framingham Heart Study. Chest133(1), 19–25 (2008).
   PubMed Web of Science ®Google Scholar
• Maclay JD, McAllister DA, Johnston S et al. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax66(9), 769–774 (2011).
   PubMed Web of Science ®Google Scholar
• MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc.2(1), 50–60 (2005).
   PubMedGoogle Scholar
• Del Rio D, Stewart AJ, Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr. Metab. Cardiovasc. Dis.15(4), 316–328 (2005).
   PubMed Web of Science ®Google Scholar
• Malhotra D, Thimmulappa R, Navas-Acien A et al. Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1. Am. J. Respir. Crit. Care Med.178(6), 592–604 (2008).
   PubMed Web of Science ®Google Scholar
• Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation112(17), 2660–2667 (2005).
   PubMed Web of Science ®Google Scholar
• Sabit R, Thomas P, Shale DJ, Collins P, Linnane SJ. The effects of hypoxia on markers of coagulation and systemic inflammation in patients with chronic obstructive pulmonary disease. Chest138(1), 47–51 (2010).
   PubMed Web of Science ®Google Scholar
• Foster GE, Brugniaux JV, Pialoux V et al. Cardiovascular and cerebrovascular responses to acute hypoxia following exposure to intermittent hypoxia in healthy humans. J. Physiol.587(13), 3287–3299 (2009).
   PubMed Web of Science ®Google Scholar
• Lahiri MK, Kannankeril PJ, Goldberger JJ. Assessment of autonomic function in cardiovascular disease: physiological basis and prognostic implications. J. Am. Coll. Cardiol.51(18), 1725–1733 (2008).
   PubMed Web of Science ®Google Scholar
• Heindl S, Lehnert M, Criee CP, Hasenfuss G, Andreas S. Marked sympathetic activation in patients with chronic respiratory failure. Am. J. Respir. Crit. Care Med.164(4), 597–601 (2001).
   PubMed Web of Science ®Google Scholar
• Clarenbach CF, Stöwhas AC, Mettler G et al. COPD is associated with increased sympathetic nervous system activation. Respiration82, 69–70 (2011) (Abstract).
   Google Scholar
• Rothwell PM, Howard SC, Dolan E et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet375(9718), 895–905 (2010).
   PubMed Web of Science ®Google Scholar
• Engstrom G, Gerhardsson de Verdier M, Dahlback M, Janson C, Lind L. BP variability and cardiovascular autonomic function in relation to forced expiratory volume: a population-based study. Chest136(1), 177–183 (2009).
   PubMedGoogle Scholar
• Stein PK, Nelson P, Rottman JN et al. Heart rate variability reflects severity of COPD in PiZ alpha1-antitrypsin deficiency. Chest113(2), 327–333 (1998).
   PubMed Web of Science ®Google Scholar
• Volterrani M, Scalvini S, Mazzuero G et al. Decreased heart rate variability in patients with chronic obstructive pulmonary disease. Chest106(5), 1432–1437 (1994).
   PubMed Web of Science ®Google Scholar
• Young RP, Hopkins R, Eaton TE. Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. Eur. Respir. J.30(4), 616–622 (2007).
   PubMed Web of Science ®Google Scholar
• Boschetto P, Quintavalle S, Zeni E et al. Association between markers of emphysema and more severe chronic obstructive pulmonary disease. Thorax61(12), 1037–1042 (2006).
   PubMed Web of Science ®Google Scholar
• Yasmin, McEniery CM, Wallace S et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler. Thromb. Vasc. Biol.25(2), 372–378 (2005).
   PubMedGoogle Scholar
• Lee SH, Goswami S, Grudo A et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat. Med.13(5), 567–569 (2007).
   PubMed Web of Science ®Google Scholar
• Thompson PD, Buchner D, Pina IL et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology and the Council on Nutrition, Physical Activity, and Metabolism. Circulation107(24), 3109–3116 (2003).
   PubMed Web of Science ®Google Scholar
• Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Anto JM. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax61(9), 772–778 (2006).
   PubMed Web of Science ®Google Scholar
• Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.171(9), 972–977 (2005).
   PubMed Web of Science ®Google Scholar
• Watz H, Waschki B, Boehme C, Claussen M, Meyer T, Magnussen H. Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. Am. J. Respir. Crit. Care Med.177(7), 743–751 (2008).
   PubMed Web of Science ®Google Scholar
• Janda S, Park K, Fitzgerald JM, Etminan M, Swiston J. Statins in COPD: a systematic review. Chest136(3), 734–743 (2009).
   PubMed Web of Science ®Google Scholar
• Lee TM, Lin MS, Chang NC. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am. J. Cardiol.101(4), 530–535 (2008).
   PubMed Web of Science ®Google Scholar
• Enriquez JR, Parikh SV, Selzer F et al. increased adverse events after percutaneous coronary intervention in patients with copd: insights from the National Heart, Lung, and Blood Institute Dynamic Registry. Chest140(3), 604–610 (2011).
   PubMed Web of Science ®Google Scholar
• Moro L, Pedone C, Scarlata S, Malafarina V, Fimognari F, Antonelli-Incalzi R. Endothelial dysfunction in chronic obstructive pulmonary disease. Angiology59(3), 357–364 (2008).
   PubMed Web of Science ®Google Scholar